RxDoctor Payments DataLook up a doctor →

Jack Rodriguez, MD

Hematology & Oncology · Natchez, MSNPI 1184623886

Payments from drug & device makers

$13,728in general payments, 2019–2025

Across 656 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Pfizer$1K
  • Novartis$1K
  • AstraZeneca$1K
  • Astellas Pharma US Inc$744
  • Merck$578
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson98$1,956
Pfizer70$1,428
Novartis38$1,408
AstraZeneca55$1,007
Astellas Pharma US Inc27$744
Merck31$578
Puma Biotechnology, Inc.36$505
Genentech USA, Inc.15$431
Sanofi18$396
Amgen19$370
Bayer18$354
Ipsen Biopharmaceuticals, Inc16$321
Takeda Pharmaceuticals U.S.A., Inc.15$305
Beigene USA, Inc.12$253
GSK11$239
E.r. Squibb & Sons, L.L.C.13$225
Regeneron Healthcare Solutions, Inc.11$222
Bristol Myers Squibb10$191
Stemline Therapeutics Inc.8$176
EMD Serono, Inc.9$169
Daiichi Sankyo Inc.8$160
Gilead7$159
Teva Pharmaceuticals USA, Inc.8$148
Incyte Corporation7$144
Eisai Inc.7$126
Array Biopharma Inc6$115
Seagen Inc.6$107
Coherus Oncology, Inc.5$99
Foundation Medicine, Inc.4$90
Boehringer Ingelheim4$89
Blueprint Medicines Corporation6$84
AbbVie4$78
Tempus AI, Inc3$66
Taiho Oncology, Inc.3$60
Spectrum Pharmaceuticals Inc.2$53
Karyopharm Therapeutics Inc.3$50
Rigel Pharmaceuticals, Inc.3$50
Epizyme, Inc.3$49
Pharmaand GmbH2$44
Tolmar, Inc.2$44
Morphosys, US Inc.2$43
Dova Pharmaceuticals2$40
Sanofi-aventis U.S. LLC2$40
Heron Therapeutics, Inc.2$39
AVEO Pharmaceuticals, Inc.2$38
Pharmacyclics LLC, An Abbvie Company2$38
Lilly USA, LLC2$37
G1 Therapeutics, Inc.2$34
Tolmar Pharmaceuticals, Inc.2$34
Adaptive Biotechnologies Corporation1$29
Acceleron Pharma, Inc.1$24
Beone Medicines USA, Inc.1$23
Kyowa Kirin, Inc.1$21
Lexicon Pharmaceuticals, Inc.1$20
Partner Therapeutics, Inc.1$19
Myriad Genetic Laboratories, Inc.1$19
ADMA Biomanufacturing LLC1$19
Genmab U.S., Inc.1$19
Pharmacosmos Therapeutics Inc.1$18
Caris MPI, Inc.1$18

How this compares

$13,728 in reported general payments places this provider in the 50th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi →

Medicare billing

Part B allowed, 2024
$3,320,769
Medicare patients
526
Services billed
147,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Natchez

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →